Quantcast

Latest Imprimis Pharmaceuticals Inc. Stories

2014-09-16 08:30:05

SAN DIEGO, Sept. 16, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced that Chief Executive Officer Mark Baum will be a presenter at the 5(th) Annual Craig-Hallum Alpha Select Conference in New York City. Mr. Baum will discuss the company's growth strategy, including its Go Dropless(TM) campaign in...

2014-09-08 08:30:23

SAN DIEGO, Sept. 8, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced the appointment of William H. Nelson to its Board of Directors, effective September 4, 2014. Mr. Nelson served as the President and Chief Executive Officer of Intermountain Healthcare, an integrated nonprofit healthcare system with 160...

2014-07-24 08:33:39

- Imprimis' proprietary ophthalmic compounded formulations now available by prescription in 32 states and territories - SAN DIEGO, July 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract...

2014-06-24 08:30:26

-- Survey highlights interest in easing patient compliance issues associated with conventional post-cataract surgery eye drop regime -- SAN DIEGO, June 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, today unveiled the results of a recent survey(1) of leading national cataract surgeons...

2014-05-28 08:31:20

-- Imprimis' proprietary ophthalmic compounded formulations now available in 25 states and territories with a physician's prescription -- SAN DIEGO, May 28, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, announced today its attendance at the upcoming 2014 Kiawah Eye Meeting...

2014-04-22 08:33:03

- Imprimis' ophthalmic formulations now commercially available with a physician's prescription - SAN DIEGO, April 22, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today its attendance and physicians' presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS)...

2014-03-25 08:28:42

--Company presentation will be webcast/available at www.imprimispharma.com-- SAN DIEGO, March 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13(th) Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET....

2014-03-04 08:30:54

Company presentation will be webcast/available at www.imprimispharma.com SAN DIEGO, March 4, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March. On Monday, March 10, 2014, Mr. Baum is...

2014-02-25 08:30:30

--First-time cataract formulation clinical data and clinical experience will be presented at a U.S. ophthalmic meeting -- SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies...

2014-02-19 08:29:46

- House to lead company's distribution strategy and pharmacy operations efforts to make and distribute Imprimis' patent-pending formulations - SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related